AstraZeneca PLC's PD-L1 inhibitor Imfinzi has secured approval in the US for endometrial cancer, providing competition for GSK plc's checkpoint inhibitor Jemperli and Merck & Co., Inc.'s behemoth Keytruda.
The US Food and Drug Administration has given the green light to the AstraZeneca therapy in combination with the chemotherapies carboplatin and paclitaxel followed by Imfinzi (durvalumab) monotherapy for adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?